Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303130 | 0.78 | PYGB (0.33) | PYGB | |
| SCHEMBL699573 | 0.71 | IGF2R (0.40) | — | |
| SCHEMBL29431574 | 0.66 | FOLH1 (0.37) | PYGB | |
| SCHEMBL21879806 | 0.66 | FOLH1 (0.37) | PYGB | |
| SCHEMBL31419474 | 0.66 | FOLH1 (0.37) | PYGB | |
| SCHEMBL2723573 | 0.66 | PYGB (0.43) | PYGB | |
| SCHEMBL6753925 | 0.66 | PYGB (0.33) | PYGB | |
| SCHEMBL9346601 | 0.66 | CA12 (0.42) | PYGB | |
| SCHEMBL28444663 | 0.65 | CA12 (0.44) | PYGB | |
| SCHEMBL28448523 | 0.65 | CA12 (0.44) | PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116983-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4154900-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | Kai Pharmaceuticals, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-3808363-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | Kai Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3539555-B1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200399309-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| EP-2776129-B2 | COMPOSITIONS FOR USE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER CHARACTERIZED BY SOFT TISSUE CALCIFICATION | KAI PHARMACEUTICALS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3539555-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | Kai Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| CN-109985228-A | Sensipar and its application method | 凯伊药品公司 | 2019-07-09 | — | — | CN | disclosed |
| US-20190194252-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10280198-B2 | Therapeutic agents for reducing parathyroid hormone levels | KAI PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| CN-101668421-B | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemia | KAI PHARMACEUTICALS INC | 2014-05-21 | — | — | CN | disclosed |
| US-20130150297-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013071262-A1 | CALCIMIMETICS AND METHODS FOR THEIR USE | KAI PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8377880-B2 | Therapeutic agents for reducing parathyroid hormone levels | KAI PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178688-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110028394-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| CN-101668421-A | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemia | KAI PHARMACEUTICALS INC | 2010-03-10 | — | — | CN | disclosed |
| EP-2086321-A2 | POLYCATIONIC CALCIUM MODULATOR PEPTIDES FOR THE TREATMENT OF HYPERPARATHYROIDISM AND HYPERCALCEMIC DISORDERS | Kai Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090023652-A1 | POLYCATIONIC CALCIUM MODULATOR PEPTIDES FOR THE TREATMENT OF HYPERPARATHYROIDISM AND HYPERCALCEMIC DISORDERS | KAI PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008067199-A2 | POLYCATIONIC CALCIUM MODULATOR PEPTIDES FOR THE TREATMENT OF HYPERPARATHYROIDISM AND HYPERCALCEMIC DISORDERS | KAI PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280198-B2 | Therapeutic agents for reducing parathyroid hormone levels | PTH1R, PTMS, TPX2 | PYGB 389/4885 |
| US-20120178688-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | PTH1R, PTMS, TPX2 | PYGB 389/4885 |
| US-20130150297-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | PTH1R, PTMS, TPX2 | PYGB 389/4885 |
| US-20240116983-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | PTH1R, PTMS, TPX2 | PYGB 526/4885 |
| US-20090023652-A1 | POLYCATIONIC CALCIUM MODULATOR PEPTIDES FOR THE TREATMENT OF HYPERPARATHYROIDISM AND HYPERCALCEMIC DISORDERS | PTH1R, CALCA, CALCRL | PYGB 2843/4885 |
| US-20190194252-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | PTH1R, PTMS, TPX2 | PYGB 389/4885 |
| US-20200399309-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | PTH1R, PTMS, TPX2 | PYGB 389/4885 |
| US-20110028394-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | PTH1R, PTMS, TPX2 | PYGB 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.